ProMIS Neurosciences Inc. Common Shares (ON)

Day range

$3.02 – $3.54

Open

$3.41

Prev close

$3.41

Volume

325.56K

Market cap

$30.58M

Shares out

8.97M

P/E

—

P/S

—

P/B

0.62

P/FCF

—

ROE

-85.5%

ROA

-74.5%

Debt/Equity

0.00

Div yield

0.00%

As of Nov 3, 2026

• Investor presentationJul 28, 2026

  On July 28, 2026 at 8:00 a.m. E.T., the Company will host a virtual webinar featuring key opinion leaders Dr. Will Mantyh, Associate Professor with Tenure, University of Minnesota Medical School and Dr. Michael Weiner, Professor Emeritus, University of California, San Francisco, to discuss the Company's six-month blinded interim data from the PRECISE-AD Phase 1b trial evaluating PMN310 in patients with early Alzheimer's disease. A copy of the presentation from the event will be available in the 'Investors' section of the Company's website.

• Equity compensation grantMay 20, 2026

  The stockholders of ProMIS Neurosciences Inc. approved an amendment (the '2025 Plan Amendment') to the Company's 2025 Stock Option and Incentive Plan (the '2025 Plan')... The 2025 Plan Amendment increases the number of Common Shares available for issuance thereunder the 2025 Plan by 900,000 Common Shares.

• Private placementJan 30, 2026

  On January 29, 2026, ProMIS Neurosciences Inc. (the "Company") entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with selected investors that qualify as "accredited investors" (the "PIPE Investors"), as defined in Rule 501(a) of Regulation D promulgated under the United States Securities Act of 1933, as amended (the "Securities Act"), for the purpose of raising approximately $75 million in aggregate gross proceeds for the Company (the "Offering") before deducting placement agent fees and other expenses payable by the Company.

• Listing compliance regainedDec 16, 2025

  On December 12, 2025, ProMIS Neurosciences Inc. (the "Company") received a written notification from the Nasdaq Stock Market Listing Qualifications Staff indicating that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market ("Nasdaq") pursuant to NASDAQ Listing Rule 5550(a)(2) ("Bid Price Rule") and that the matter is now closed.

• Stock splitNov 24, 2025

  On November 17, 2025, the Board approved a reverse stock split of the Common Shares at a ratio of one-for-twenty-five. Effective as of 12:01 a.m. Eastern Time on November 28, 2025, the Company filed the Articles Amendment to effect one-for-twenty-five reverse stock split of its Common Shares (the 'Reverse Stock Split'). As a result of the Reverse Stock Split, every 25 Common Shares issued or outstanding were automatically reclassified into one validly issued, fully-paid and non-assessable new Common Share.

Days to cover

7.1

Short interest

245.84K

Avg volume

34.43K

As of Oct 15, 2026 · reported to FINRA twice monthly.

• Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight
  positiveGlobeNewswire Inc.· Oct 22, 2026
• ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
  positiveGlobeNewswire Inc.· Jul 28, 2026
• ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
  positiveGlobeNewswire Inc.· Jul 14, 2026
• ProMIS Neurosciences Announces Reverse Stock Split
  neutralGlobeNewswire Inc.· Nov 24, 2025
• ProMIS Neurosciences Announces Private Placement Financing
  positiveGlobeNewswire Inc.· Jul 28, 2025